annb0t
Top 20
Aug 3 (Reuters) - The U.S. Food and Drug Administration had rejected Mesoblast's cell therapy for children under 12 years of age for treating a type of complication that occurs after a stem cell or bone marrow transplant, the company said on Thursday.
The health regulator required more data to support marketing approval for the company's lead product remestemcel-L, Mesoblast said in a statement.
The rejection deals a blow to Mesoblast's hopes for a potential launch of the therapy, especially a...
>>> Read more: FDA rejects Mesoblast's cell therapy for bone marrow transplant complications
The health regulator required more data to support marketing approval for the company's lead product remestemcel-L, Mesoblast said in a statement.
The rejection deals a blow to Mesoblast's hopes for a potential launch of the therapy, especially a...
>>> Read more: FDA rejects Mesoblast's cell therapy for bone marrow transplant complications
